This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events (MAKE) in approximately 40 participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from baseline in NGAL levels
Timeframe: Baseline(Day -1) to Day 7
Change from baseline in sCr levels
Timeframe: Baseline(Day -1) to Day 7
Change from baseline in eGFR
Timeframe: Baseline(Day -1) to Day 30